A carregar...
Therapeutic potential of JAK2 inhibitors
The discovery of an activating tyrosine kinase mutation JAK2V617F in myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) has resulted in the development of JAK2 inhibitors, of which several are being evaluated in phase I/II clin...
Na minha lista:
| Publicado no: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5166576/ https://ncbi.nlm.nih.gov/pubmed/20008249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/asheducation-2009.1.636 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|